Athersys, Inc, a biotechnology company, focuses on the research and development in the field of regenerative medicine.
Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.
ATHX's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase 2 study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase 2 clinical study for treating patients with acute myocardial infarction; and, which is in Phase 1/2 clinical study for treating patients with acute respiratory distress syndrome, as well as completed Phase 1 clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients; and 5HT2c agonists for the treatment of obesity and other conditions.
Athersys has license and collaboration agreements with Healios K.K. and Chugai Pharmaceuticals Co., Ltd. to develop and commercialize MultiStem cell therapy for ischemic stroke; RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb to provide cell lines expressing well validated drug targets for compound screening and development.
Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
October 23, 2013
Running “sore” on share price growth
October 23, 2013
The Early Movers
October 22, 2013
Itchy trigger fingers
October 22, 2013
RegMed “dead money” continues while broader market spikes
October 22, 2013
The Early Movers
October 21, 2013
Crawling through the regulatory and pricing “wires”
October 21, 2013
The Early Movers
October 18, 2013
The ice cubes are marinating early, after this week!
October 18, 2013
The Early Movers
October 17, 2013
Be prepared to get kick again as the can goes further down the road
35 companies, 1 interpreter!
Insight, foresight and recommendation
Athersys (ATHX) – Started 1/18 at $1.81, dropping on 2/1 to $1.76 and was trading at $1.44 on 2/16 ... after initiating a follow-on equity facility to a current facility. Under the new agreement, ATHX has the right to sell up to $100 million of its common stock to Aspire Capital under certain conditions over a three-year period. In conjunction with the new facility, Aspire made an initial investment of $1 million at a price of $2.00 per share. As of 12/31/17t, ATHX had approximately $29.3 million of cash and cash equivalents available to fund operations. DON’T look for follow through appreciation as the stock based debt facility will be selling shares into ANY strength …
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.